Scarica l'app Stockscreener
742.00
1.08%
-8.11
Dopo l'orario di chiusura:
741.01
-0.99
-0.13%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché REGN Giù?
Forum
Previsione
Precedente Chiudi:
$750.11
Aprire:
$742.12
Volume 24 ore:
924.52K
Relative Volume:
0.85
Capitalizzazione di mercato:
$76.64B
Reddito:
$14.25B
Utile/perdita netta:
$4.58B
Rapporto P/E:
17.76
EPS:
41.7701
Flusso di cassa netto:
$3.88B
1 W Prestazione:
-5.76%
1M Prestazione:
+13.84%
6M Prestazione:
+51.18%
1 anno Prestazione:
-2.67%
Intervallo 1D:
$731.00
$747.00
Intervallo di 1 settimana:
$731.00
$790.98
Portata 52W:
$476.49
$800.99
Regeneron Pharmaceuticals Inc Stock (REGN) Company Profile
Nome
Regeneron Pharmaceuticals Inc
Settore
Industria
Telefono
(914) 847-7000
Indirizzo
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY
Confronta REGN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
REGN
Regeneron Pharmaceuticals Inc
|
742.00 | 78.84B | 14.25B | 4.58B | 3.88B | 41.77 |
|
VRTX
Vertex Pharmaceuticals Inc
|
433.15 | 107.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.93 | 60.05B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
915.36 | 55.10B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
206.60 | 45.09B | 447.02M | -1.18B | -906.14M | -6.1812 |
Regeneron Pharmaceuticals Inc Stock (REGN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-11-24 | Iniziato | HSBC Securities | Buy |
| 2025-11-24 | Ripresa | Truist | Buy |
| 2025-11-13 | Iniziato | Scotiabank | Sector Perform |
| 2025-08-14 | Iniziato | Rothschild & Co Redburn | Buy |
| 2025-06-30 | Downgrade | Argus | Buy → Hold |
| 2025-05-30 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-05-30 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2025-05-14 | Aggiornamento | Citigroup | Neutral → Buy |
| 2025-04-22 | Ripresa | Cantor Fitzgerald | Overweight |
| 2025-02-05 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2025-01-16 | Downgrade | UBS | Buy → Neutral |
| 2024-12-10 | Ripresa | BofA Securities | Underperform |
| 2024-11-15 | Iniziato | Wolfe Research | Outperform |
| 2024-11-14 | Iniziato | Citigroup | Neutral |
| 2024-09-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2024-03-12 | Iniziato | Bernstein | Outperform |
| 2024-01-12 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-11-09 | Iniziato | Deutsche Bank | Hold |
| 2023-11-03 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2023-08-21 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2023-08-21 | Reiterato | Oppenheimer | Perform |
| 2023-06-28 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2023-03-27 | Aggiornamento | SVB Securities | Market Perform → Outperform |
| 2023-03-24 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-03-23 | Aggiornamento | Raymond James | Underperform → Mkt Perform |
| 2023-01-30 | Aggiornamento | Cowen | Market Perform → Outperform |
| 2023-01-20 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2022-10-26 | Downgrade | Raymond James | Mkt Perform → Underperform |
| 2022-10-17 | Downgrade | Evercore ISI | Outperform → In-line |
| 2022-09-09 | Aggiornamento | Jefferies | Underperform → Hold |
| 2022-09-09 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2022-07-25 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2022-07-13 | Iniziato | Cantor Fitzgerald | Neutral |
| 2022-06-06 | Iniziato | Jefferies | Underperform |
| 2022-05-23 | Iniziato | SVB Leerink | Outperform |
| 2022-01-05 | Downgrade | BofA Securities | Neutral → Underperform |
| 2022-01-03 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2021-12-15 | Downgrade | Bernstein | Outperform → Mkt Perform |
| 2021-12-09 | Ripresa | Wells Fargo | Overweight |
| 2021-12-07 | Ripresa | Cowen | Market Perform |
| 2021-12-06 | Iniziato | Goldman | Buy |
| 2021-11-19 | Ripresa | BMO Capital Markets | Outperform |
| 2021-11-05 | Downgrade | The Benchmark Company | Buy → Hold |
| 2021-06-29 | Iniziato | H.C. Wainwright | Buy |
| 2021-01-25 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2021-01-13 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2021-01-08 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-10-05 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2020-08-20 | Downgrade | The Benchmark Company | Buy → Hold |
| 2020-07-09 | Aggiornamento | SunTrust | Hold → Buy |
| 2020-05-26 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2020-04-28 | Downgrade | Citigroup | Buy → Neutral |
| 2020-04-17 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2020-04-08 | Iniziato | The Benchmark Company | Hold |
| 2020-03-31 | Iniziato | Wolfe Research | Peer Perform |
| 2020-02-27 | Iniziato | Barclays | Overweight |
| 2020-02-26 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2020-02-26 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2020-02-25 | Aggiornamento | Jefferies | Hold → Buy |
| 2020-02-11 | Aggiornamento | Argus | Hold → Buy |
| 2019-12-24 | Iniziato | Raymond James | Mkt Perform |
| 2019-12-16 | Downgrade | Evercore ISI | Outperform → In-line |
| 2019-12-13 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2019-11-12 | Iniziato | SunTrust | Hold |
| 2019-11-07 | Aggiornamento | Citigroup | Neutral → Buy |
| 2019-10-17 | Ripresa | BofA/Merrill | Neutral |
| 2019-09-23 | Aggiornamento | Guggenheim | Neutral → Buy |
Mostra tutto
Regeneron Pharmaceuticals Inc Borsa (REGN) Ultime notizie
COPD Market to Expand Significantly by 2034, States DelveInsight Report | Genentech, GlaxoSmithKline, Verona Pharma, Regeneron Pharma, Sanofi, MedImmune, EpiEndo Pharma, Tetherex Pharma, AstraZeneca - Barchart.com
Follicular Lymphoma Market Predicted to See Upsurge Through - openPR.com
REGN & Tessera Collaborate to Develop Gene-Editing Therapy for AATD - Yahoo Finance Singapore
Akeso’s Goals Beyond Ivonescimab: ‘We Can Hit Vertex And Regeneron-Level Innovation’ - Citeline News & Insights
Regeneron and Tessera partner to develop gene therapy for AATD - MarketScreener
Regeneron and Tessera ink $150M gene editing partnership in AATD - The Pharma Letter
Regeneron stock maintains Outperform rating at Bernstein following Tessera deal - Investing.com UK
Regeneron Pharmaceuticals, Inc. $REGN Stake Increased by Mackenzie Financial Corp - MarketBeat
Sepio Capital LP Boosts Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
What Wall Street predicts for Regeneron Pharmaceuticals Inc. stock priceJuly 2025 Macro Moves & AI Enhanced Trading Signals - Newser
Quadrant Capital Group LLC Sells 688 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Distillate Capital Partners LLC Has $14.69 Million Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals (REGN): Is There More Value Ahead After Recent Uptrend? - simplywall.st
Can Regeneron Pharmaceuticals Inc. stock maintain growth trajectoryJuly 2025 Institutional & High Accuracy Buy Signal Tips - Newser
Will Regeneron Pharmaceuticals Inc. (RGO) stock benefit from sector leadershipNew Guidance & Smart Allocation Stock Reports - Newser
Tessera Will Team With Regeneron On Gene-Writing Therapy For AATD - Citeline News & Insights
Regeneron Puts Up $150M to Partner on Tessera Gene-Editing Med for Rare Liver & Lung Disorder - MedCity News
Regeneron Pharmaceuticals Inc. stock underperforms Monday when compared to competitors - MarketWatch
Regeneron (REGN) Invests $150M in Tessera's Gene Editing Therapy - GuruFocus
Regeneron inks deal with Tessera to develop gene editing therapy - Seeking Alpha
Regeneron and Tessera advance TSRA-196 toward IND/CTA filings - CRISPR Medicine News
Regeneron and Tessera join forces to forge in vivo AATD gene therapy - Yahoo Finance
Somerville biotech secures $150M upfront from Regeneron for gene-editing treatment - The Business Journals
Regeneron Invests $150 Million In Tessera To Advance One-Time Gene Therapy For Rare Genetic Disorder - Benzinga
Regeneron inks gene editing deal with startup Tessera - BioPharma Dive
5 Healthcare Names to Watch as Sector Rotation Is in Full Swing - Finviz
Regeneron and Tessera collaborate on TSRA-196 - BioWorld MedTech
REGN Gains 21.5% in a Month: Time to Buy, Sell or Hold the Stock? - Yahoo Finance
Regeneron, Tessera Therapeutics Partner to Develop & Commercialize TSRA-196 - Contract Pharma
Regeneron Makes $275M Gene Editing Play With Tessera Partnership Targeting AATD - BioSpace
Regeneron and Tessera Therapeutics to jointly develop TSRA-196 - MarketScreener
Regeneron and Tessera partner on gene therapy for alpha-1 deficiency - Investing.com Australia
Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by New York State Common Retirement Fund - MarketBeat
Regeneron (REGN) Partners with Tessera to Advance Gene Therapy f - GuruFocus
Regeneron, Tessera Enter Collaboration To Develop TSRA-196 - Nasdaq
Regeneron (NASDAQ:REGN) in $150M Tessera pact on TSRA-196 AATD gene therapy - Stock Titan
Norges Bank Invests $628.15 Million in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Inceptionr LLC Invests $328,000 in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Global Retirement Partners LLC Acquires New Shares in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Should You Buy This Biotech Stock That Just Gained 5% in 1 Day? - The Globe and Mail
Virtus Investment Advisers LLC Acquires 366 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Virtue Capital Management LLC Acquires New Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
State Board of Administration of Florida Retirement System Has $54.71 Million Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Korea Investment CORP Cuts Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Steward Partners Investment Advisory LLC Has $2.25 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Loomis Sayles & Co. L P Acquires 305,089 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Quadrature Capital Ltd Takes $36.97 Million Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Groupama Asset Managment Sells 22,742 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Grantham Mayo Van Otterloo & Co. LLC Has $34.27 Million Stake in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Johnson Financial Group Inc. Purchases 327 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN Shares Purchased by Vinva Investment Management Ltd - MarketBeat
Regeneron Pharmaceuticals Inc Azioni (REGN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.28%
2.28%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):